Fully funded13 Jul 2020 14:05
The net proceeds of the Fundraising, together with its existing cash resources, are expected to enable the Company to continue to fund its operations to at least four key clinical study datapoints (as detailed below) expected in H2 2020 and Q1 2021.
At least 4 clinical study data points. Any one of these that's a success will propel the sp significantly. The placing wasnt mega discounted or mega huge. For me this cements the uncertainty around funding... and I'm willing to wait and see what the clinical outcomes are in the trials.